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Abstract: Guidelines for growing insulin crystals of a uniform size are formulated and tested 
experimentally. A simple theoretical model based on the balance of matter predicts the time 
evolution of the crystal size and supersaturation. The time dependence of the size is checked 
experimentally. The experimental approach decouples crystal nucleation and growth 
processes according to the classical nucleation-growth-separation principle. Strict control over 
the nucleation process is exerted. Crystalline substance dispersity is predetermined during the 
nucleation stage of a batch crystallization process. To avert nutrition competition during the 
crystal growth stage, the number density of nucleated crystals is preset to be optimal.  
 
Keywords: A1. Growth models; A1. Nucleation; A2. Growth from solutions; A2. Equally-
sized protein crystals; B1. Biological macromolcules; B1. Proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Corresponding author: e-mail: nanev@ipc.bas.bg; Phone: (359-2) 8719306; Fax: (359-2) 
971 26 88. 
 2 
1. Introduction 
Insulin is a life-essential polypeptide hormone (protein), the deficiency or resistance to 
which cause profound deregulation of metabolic processes resulting in disorders such as 
diabetes mellitus and obesity. Insulin crystallization is interesting in its own right since it 
represents a unique case of ‘benign’ protein crystallization; in contrast, crystallization of other 
proteins, formation of crystal-like ordered aggregates, and fibrilization of misfolded proteins 
are reasons for severe degenerative illnesses, such as cataract, sickle-cell anemia, Alzheimer 
disease, Parkinson disease, Huntington disease, etc. 
The rationale behind the present study is associated with the production of 
monodisperse crystalline pharmaceuticals that have gained significant interest. Protein-based 
pharmaceuticals are not administered per os because they are denatured by the gastric juice 
(pH ~ 1÷3) containing pepsin. Instead, they are injected, delivered by implants, insulin 
“pumps”, or inhalators. Crystalline forms of pharmaceuticals have shown significant 
pharmacokinetic benefits in achieving optimal concentration and higher bioavailability, by 
versatility in routes of drug administration [1–4]. Crystalline forms of insulin are added 
frequently to an amorphous drug to provide extended control of blood glucose in people with 
diabetes. The reason is that while amorphous drugs dissolve very fast and render almost 
immediate but short-lasting concentration increase, the crystals dissolve relatively slowly. 
Moreover, when crystals are mono-disperse, they dissolve in a similar way. That is how a 
sustainable and adjustable release of a therapeutic agent may be ensured; release profiles 
could be modulated successfully using morphology differences of protein crystals. In contrast, 
in a system composed of differently sized crystals the smallest particles dissolve faster than 
the larger crystallites and with some crystals disappearing from the system, drug 
concentration drops. For diabetes treatment long-acting crystalline insulin formulations have 
been applied over the last 50 years. It is reasonable to expect that to secure prolonged action 
and avoid the inconvenience and stress due to frequent injections such drug formulations 
would be sought for other crystalline drugs [5] as well (i.e. interferons, human growth 
hormone, etc.). 
The crystal size distribution in the drug can be of crucial importance [6]. Crystals 
smaller than 15 μm are needed to avoid clogging when administered by a fine-needle 
injection [7] (required to reduce pain) while larger than 10 μm crystals are indispensable for 
ensuring protracted drug effect [1]. Therefore, manufacturing crystals of desired size 
distribution [8] proves to be a major objective for the pharmaceutical industry. 
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High technology methods, such as attenuated total reflection-Fourier transform 
infrared (ATR-FTIR) spectrometry, for instance, have been developed recently for controlling 
protein solution concentrations in crystallization processes [9 – 11]. The latter technique is 
applied to detect the metastable limit. On this basis advanced approaches to automated direct 
nucleation control of crystal size distribution in pharmaceuticals have been elaborated and 
applied to perfection.  
The present study applies a classical principle established by Tammann [12] that 
requires a strict time-wise separation of nucleation and growth stages in the course of the 
continuous crystallization process. This principle has been successfully applied in 
crystallization of glasses, proteins, and electro-crystallization, etc. The present study considers 
a protocol devised by the authors for a novel application of the method’s thermal variant for 
growing insulin crystals of a desired uniform size. Since the proposed method is of a low 
technology nature, it is a very simple one. The procedure is easy to perform and does not 
require sophisticated equipment. However, with the abovementioned high-tech method it is 
possible to fine tune the crystallization process under the protocol. 
 
2. Analytical model 
The simplest way to grow equally sized crystals is considered to be simultaneous 
nucleation of all crystals and parallel growth. This provides for predetermined crystalline 
phase dispersity, i.e. the number density, N [cm-3] of the crystals grown is fixed. The present 
study looks at the nucleation-growth separation principle (NGSP) adapted to match the 
protocol devised to obtain a constant number density N of nucleated crystals that grow further 
to produce equally sized crystals. 
It is clear that in a batch crystallization process, the initial solution concentration co is 
decreasing systematically. Thus, the concentration c at a given time point t is a result of the 
gradual supersaturation exhaustion that is due to the crystal growth. So, the difference (co - c) 
is the amount that was consumed in order N crystals to grow to the same size ℓ. The mass 
balance shows that 
ℓ  = [Ω (cо – c)/N]1/3, and         (1) 
c = co – Nℓ 3/Ω          (1’)  
where Ω ≈ 1 сm3/gr is the specific volume; Ω stands for the density change that undergoes the 
substance during the transfer from dissolved to solid state. 
Evidently, the quantity Ω(co – ce)/N defines the maximal size λ to which the crystals 
could grow given the supersaturation (co – ce) is exhausted  
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λ = [Ω(co – ce)/N ]1/3         (2)  
where ce is the equilibrium concentration. 
It is worth noting that the initial solution concentration cо remains practically 
unchanged after crystal nucleation. The concentration cn of the crystallizing solution after 
nucleation termination is obtained to be 
cn = cо - NV/Ω          (3) 
where V is nucleus volume. Since typically V ≈ 10-15 сm3 (e.g. insulin nucleus encompasses 
one to two hexamers [13], each 5 nm in size), practically cn = cо, even with the highest 
experimental N values. 
Once the nucleation step is overcome, the nuclei grow into macroscopic crystals. It is 
known that with protein crystals the growth proceeds at high supersaturation levels. Therefore, 
the growth rate R of an individual crystal face is proportional to the supersaturation [14] 
R = βΩ(c – ce)          (4)  
where β [сm/s] is a kinetic coefficient, the  difference (c – ce) is the driving force of the crystal 
growth. For simplicity purposes only cubic crystals are considered here, which grow in 
uniform size. The change of ℓ is determined by the growth of two opposite crystal faces  
dℓ/dt = 2R = 2βΩ(c – ce)         (5)  
Now with the help of eq. (1’) we reorganize eq. (5) to obtain  
dℓ/dt = 2Nβ [Ω(co – ce)/N – ℓ 3]        (6)  
To nondimensionalize the problem we use λ from eq. (2) and introduce dimensionless 
size L ≡ ℓ/λ, and obtain 
dL/dt = 2Nβλ2 (1 - L3)         (7)  
The quantity 1/τ ≡ Nβλ2 has dimension of s-1 and can be used to introduce 
dimensionless time T ≡ t/τ, to arrive finally at 
dL/dT = 2(1 - L3)          (8)  
The integral of eq. (8) can be found in any extended table of integrals, or by using 
some of the numerous online integrators. To obtain the T - L dependence the integration 
constant is found from the condition L = 0 at T = 0. Thus 
T = 0.5 {-0.3023+(1/6)log[(L2+L+1)/(L-1)2] +(1/sqrt(3) Arctg[(2L+1)/sqrt(3)]}        (9) 
Concentration (supersaturation) decrease with time is of importance from a 
technological perspective because when supersaturation depletion becomes significant, crystal 
growth rate drops below the technologically interesting limits. For that reason we recall eq. 
(1’) for the mass balance of the growth up to the moment t and re-organize it by subtracting ce 
from both sides 
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c - ce = co - ce – Nℓ 3/Ω         (10) 
and divide further both sides by (co - ce) to obtain 
(c - ce)/(co - ce) = 1 – (Nℓ 3/Ω)/(N λ 3/Ω)                                                                     (11) 
where we use the definition of the maximal achievable size λ from eq. (2). On the left hand 
side of eq. (11) we have a quantity that could be defined as dimensionless supersaturation σ ≡ 
(c - ce)/(co - ce), which is 1 in the beginning of the growth and reaches 0 at its end.  Thus we 
get 
σ = 1 – L3                                                                                  (12) 
which is half the derivative of L with respect to T in eq. (8). Combining eqs. (9) and (12) we 
obtain numerically the universal curve of our model in the (T, σ, L)-space as given below. 
 
 
 Fig. 1 The universal curve of the model in the (T, σ, L)-space. 
 
Equation (12) contains the possibility to calculate the solution concentration that 
corresponds to the measured crystals size, and compare the theoretical prediction with the 
actual solution data obtained by ATR-FTIR spectrometry. 
 
3. Experimental Section 
3.1. Description of a protocol for growing insulin crystals of a uniform desired size 
distribution. 
The classical NGSP was used to manage a process of batch protein crystallization 
intended to produce equally-sized insulin crystals. A batch crystallization method was 
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employed because the results of this study might be applied on a large scale as well. The 
approach proved to be capable of meeting the requirements of the analytical model used.  
As seen in Ostwald-Miers phase diagram, (e.g. [15]) the nucleation demands higher 
supersaturation than that which is sufficient for subsequent crystal growth. Even in cases of a 
quite narrow metastable zone such separation is possible by means of NGSP thermal variant 
because temperature can be maintained with a routine accuracy of 0.01oC. Under NGSP, 
nucleation period is set short (Fig. 2) so as to ensure crystal formation only. Crystals have no 
time to grow, remain small and do not consume an appreciable amount of solute. NGSP has 
been originally devised [12] due to the principle impossibility to observe elementary acts of 
crystal nucleation at a molecular scale. To make nucleated crystallites visible under light 
microscope, supersaturation is rapidly lowered after expected nucleation onset. Such lowering 
is below the upper limit of the so-called metastable zone, i.e. below the threshold limiting the 
crystal nucleation process (Fig. 2). In this way the system is deprived of its capability to 
further produce nuclei and only the existing super-critically sized clusters can grow to 
microscopically visible crystals. 
                                                                                 
               Fig. 2      Fig. 3  
 
Fig. 2 Schematic presentation of the classical principle for time-wise nucleation and 
growth stages separation; inclined fronts of supersaturation jumps indicate that the system 
requires certain time to respond to any physical change (including temperature jumps, etc.). 
Fig. 3 Rhombohedral insulin crystals (interference contrast by differential image 
splitting). 
 
Insulin solubility is dependent on temperature and hence, temperature was used as an 
instrument in NGSP. The dependence is normal, meaning that solubility rises with 
temperature increase. Hence, a separation experiment involves a rapid quench of the 
metastable solution to the nucleation temperature that corresponds to the supersaturation of 
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interest (Fig. 2). For the purposes of the present study insulin solutions were cooled to 4oC. 
That temperature was maintained for the nucleation times chosen by the experimenter. After 
nucleation time elapsed, the temperature was increased abruptly and the nucleated crystals 
were allowed to grow to microscopically visible sizes. 
The so-called quasi-2D-cells [13] were used as crystallizing solution containers. Such 
a custom-made all-glass cell represents a pair of disk-shaped optical glass plates welded in an 
exactly parallel position at a distance of 0.5 mm (rarely 0.1 mm). Crystallization took place in 
the thin solution layer confined within the gap between the two glass plates. The cells allowed 
perfect cleaning and excellent microscopic observation (Fig. 3). The main advantage of such a 
cell was, however, the possibility to impose rapid supersaturation shifts. Water baths were 
used for that purpose. The cell containing insulin solution was immersed into water of the 
temperature desired [13]; water cooling was proven to be more efficient than air cooling [16]. 
Cell volume was 0.35 cm3. All crystals inside the cell were count from CCD-camera 
photo images (but not directly in the microscope). A grid was drawn initially on the cell’s 
upper glass plate with differently colored felt-tip pens in order to distinguish the meshes 
easily. The procedure of crystal counting was repeated three times. 
 
3.2. Experimental procedure. 
Insulin from porcine pancreas was pursued from SIGMA (Denmark, Lot # 
080M1589V). It was crystallized without further purification. Initially, weighed amount of 
insulin was dissolved in diluted hydrochloric acid; then, citrate buffer and ZnCl2 were added 
in small portions and the solution contained in the Eppendorf test tube was heated to 50 оС. 
Several quasi-2D-glass cells were brought to the same temperature, together with the test 
tube. Finally, acetone was added to the solution and the latter was transferred in the 
(preliminary) heated 2D-glass cells. All cells were closed, attached to a specially designed 
vibrationless holder and immersed in a water bath of the desired temperature. The 
crystallization conditions were similar to those described in [13]: 0.001 M HCl and 0.005 M 
ZnCl2, pH = 7 by 0.05 M trisodium citrate, 15% (v/v) acetone. 
 
4. Results and Discussion 
4.1. Selection of the growth temperatures. 
One and the same quantity of crystallizing matter can be divided in different ways – in 
a relatively larger number of smaller crystals or in a lesser number of larger species. In the 
case under consideration the advantage of NGSP is that the number density of growing 
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crystals is constant; it is preset during the nucleation stage, and a one-to-one ratio of nuclei 
formed to crystals grown to visible sizes is achieved, the latter coming as a result of 
precautions taken to not only prevent new nuclei formation but also avoid nuclei loss due to 
dissolution. The growth temperatures range providing a constant number density of nucleated 
crystals was investigated in order to secure the latter conditions. To this end temperature 
increase necessary for the transition from nucleation to growth stage was varied. 
The experimental studies under consideration revealed a growth temperature range 
where the number density N of nucleated crystals remained virtually constant [17], within the 
statistical data scatter. Batch insulin crystallization was carried out by maintaining nucleation 
parameters the same. Two typical insulin concentrations, 5.0 mg/ml and 7.0 mg/ml, were 
selected on the grounds of the authors’ experience in insulin crystallization. As it is seen in 
Fig. 4, number density N [cm-3] of crystals grown is nearly constant within the temperature 
range of at least ΔT ≈ 4 to 5oC. 
 
            a.                                       b. 
Fig. 4a, b Plots of number densities N of nucleated insulin crystals vs. growth 
temperature, oC. Insulin concentrations are 5.0 mg/ml (Fig. 4a) and 7.0 mg/ml (Fig. 4b); in all 
cases crystal nucleation is initiated by cooling down to 4oC for 10 min. 
 
Within the growth temperature range of 18 to 21oC the 5.0 mg/ml insulin solution 
produced crystals of different sizes, indicating the occurrence of a secondary nucleation. The 
natural explanation is that some crystals nucleate only latter, during the growth stage, and thus 
- remain smaller. Besides, within the temperature range of 22 to 26 oC where the number 
density N of the grown crystals is nearly constant, crystals were also nearly equal in size. On 
the other hand, nuclei started dissolving at the brink of the solubility curve (temperature 
28.5±0.5oC) and no crystals were observed at higher growth temperatures. It can be deduced 
here that the temperature range of ΔT ≈ 22 to 26 oC corresponds to the width of the metastable 
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zone. The result obtained with concentration of 7 mg/ml (Fig. 4b) was similar though showing 
a larger data scattering within the metastable zone. Similarly, all crystals dissolved at 
temperatures above 28oC. 
 
4.2. Experimental validation of the methodology. 
The immanent assumption of our theoretical treatment in Section 2 is that the crystals 
grow independently, i.e. without overlapping of their diffusion fields. Since it was not clear a 
priory to what extent the narrow insulin crystal size distribution might be disturbed during 
subsequent growth, systematic experimental investigations were performed to validate the 
methodology employed in the study. They confirmed that this methodology provided protein 
crystals of a narrow size distribution. Applying the methodology rendered 1.5 times less 
crystal size variations (see Table 1) while crystals of 4 - 5 times larger size than the smallest 
particles were observed when NGSP was not applied. It was noticed, however, that even with 
NGSP, size variations were larger at lower insulin concentrations and the variations 
augmented with growth time. In some cases several larger crystals were observed at 
extremely long growth times but their number was not statistically significant; other effects 
like Ostwald ripening etc. also might took place. 
Direct quantitative comparison was performed with insulin crystals of nearly equal 
average size, 18 μm and 17.6 μm (Table 1) reached after growth for about 1 day, growth 
temperatures being taken from Fig. 4. Note that two different initial concentrations mentioned 
above, co = 5 mg/ml and co = 7 mg/ml found application. The only difference was that in the 
former case the crystals were nucleated during longer time, 40 minutes, while in the second 
case the nucleation time was 10 minutes only. It is worth noting that the nucleation times 
(relatively short/longer time) were selected on the grounds of the authors’ experience in 
insulin crystal nucleation.  For instance, nucleation times shorter than about 10 min were 
excluded because any interference caused by cell cooling and heating transition periods had to 
be avoided. As it is seen in Table 1, the deviation in the approximately equal crystal size 
achieved after a day growth was more than twice smaller when using the second combination 
of nucleation conditions (nucleation time 10 min at higher insulin concentration co = 7 mg/ml) 
compared to the longer nucleation time, 40 min at co = 5 mg/ml. Indeed, prolonged growth 
time resulted in larger crystal size variations however, such variations being systematically 
less for shorter nucleation time (Table 1). There is a simple explanation to the observed 
phenomenon: obviously crystal nucleation is initiated almost simultaneously and the shorter 
the nucleation time, the more simultaneously it occurs. Thus, the crystals begin to grow 
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(almost) simultaneously and provided they grow without competing for nutrition in a similar 
way (in view of the approximately equal screw dislocation density) the crystals become nearly 
equal in size. 
 
Table 1. Average sizes and size-variations of insulin crystals grown by NGSP 
Insulin concentration and 
nucleation time 
Crystal growth time 
about 1 day about 2 days about 3 days 
5 mg/ml, 40 minutes 18.0±9 μm 32.0±17 μm 57.4±29 μm 
7 mg/ml, 10 minutes 17.6±4 μm 28.0±11 μm 39.0±15 μm 
 
 It is worth noting that insulin crystals from co = 5 mg/ml grow larger in size because 
their number density N is about four times lesser than that for co = 7 mg/ml (Fig. 4). 
 
4.3. Comparison of the analytical model with experimental data 
The experimental results from Table 1 are compared with the the predictions of the 
analytical model described in Section 2. The graphical dependence L vs. T, represented by the 
solid line in Fig. 5, is resulting from the solution of eq. (9). It is the projection in the L - T 
plane of the universal curve plot from Fig. 1. 
 
        Fig. 5.           Fig. 6. 
Fig. 5. Evolution of the dimensionless size L vs. dimensionless time, T as predicted by 
eq. (9), compared with the experimental data in Table 1, and rescaled  using the characteristic 
length- and time-scales, λ and τ with fitting value of β = 3.45x10-6 cm/s. L* is estimated for 
the experimental data set with co = 7mg/ml. L*≡ L*7mg/ml is shown. 
Fig. 6. Critical crystal size ℓ* above which the diffusion fields of the growing crystals, 
having number density N, start to overlap, eq. (13). 
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Fig. 5 shows the limit to which the analytical model used may be applied. Evidently, 
nutrition competition (if present) may disturb size distribution. Such a competition can be 
prevented by ensuring that the distance Λ between the crystals is sufficiently larger than the 
thickness of the doubled Nernst diffusion layer, δ. At a hypothetical uniform crystal 
distribution in solution bulk we have Λ = (ℓ + 2δ) = N -1/3. Therefore, the lower number 
density N the longer is the crystal growth without nutrition competitions. That is why we start 
our consideration with the experimental results for initial insulin concentration co = 5 mg/ml, 
which means N = 1500 cm-3 (Fig. 4). Unfortunately, there are no measured β values. For that 
reason to achieve best fit with the prediction we treat the kinetic coefficient of the crystal face 
β as a free parameter and the value β = 3.45x10-6 cm/s was chosen to allow for the data from 
the experimental set with initial insulin concentration co = 5 mg/ml to remain on the 
theoretical curve (Fig. 5.a.). It is worth noting that this value is quite reasonable; despite the 
high supersaturations applied the protein crystals grow slowly. Since β is independent on the 
concentration the same value was used to rescale the data from the experimental set with 
initial insulin concentration co = 7 mg/ml. Note that due to this rescaling of the data, the 
values of T for the two different data sets also differ although the real sizes are taken at same 
time intervals of 1, 2 and 3 days. 
The most important conclusion from the plot is that the experimental set with co = 7 
mg/ml shows significant deviation from the theoretical prediction and this may be attributed 
to an earlier overlapping of the diffusion fields of neighboring crystals, what contradicts to the 
assumptions of our analytical model. Since the dependence shown in L - T coordinates seems 
to be linear one, speculating further we could extrapolate it back to estimate the critical size 
L*≡ L*7mg/ml, after which the crystal growth starts to deviate from that of independent crystals, 
and it is roughly L* = 0.1, which is shown with and arrow on the plot; or, back to dimensional 
size, ℓ*7mg/ml = 10 μm. It defines a “growth affected” volume” (ℓ*7mg/ml + 2δ)3, and this 
volume should become of the order of 1/N  
(ℓ*7mg/ml + 2δ)3 ≈ 1012 μm3/N, => δ ≈ 270.2 μm      (13)  
Note that this δ value is a realistic one. Now, based on it, one could estimate the 
critical value ℓ*5mg/ml, after which the experimental trials with co = 5 mg/ml are expected also 
to depart from the assumption for non-competing growing crystals. Thus, ℓ*5mg/ml ≈ 333 μm, 
which is well above the maximal size 130 μm that may be achieved with co = 5 mg/ml and N 
= 1500 cm-3. This justifies our assumption that all data for sizes obtained with co = 5 mg/ml, 
including the third day of growth,  remain on the theoretical curve in Fig. 5a. 
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 And vice versa, ℓ* can be calculated and plotted (Fig. 6) from eq. (13). The reason to 
do this is to see the effect of small δ variations which may be exerted on ℓ*, that is to estimate 
the consequences such variations would have on the transition to growth of crystals with 
overlapping diffusion fields. As seen, relatively small variations have significant 
consequences; supposing δ = 220 μm (instead of δ = 270 μm), for N = 6000 [cm-3] ℓ* would 
have been 111 μm, while with δ = 320 μm, ℓ* for N = 1500 [cm-3] will be 230 μm, which, 
however, is still above the maximal achievable size of 130 μm with the initial insulin 
concentration of co = 5 mg/ml. 
Concluding we may note that, as it is well known, the linear dependence holds true 
only at sufficiently high supersaturations. According to BCF theory, a deviation from linearity 
should be observed when the actual supersaturation falls below certain threshold, which also 
limits the applicability of our analytical model. On the other hand, diffusion-limited crystal 
growth has to dominate our experiments due to the suppression of the natural convections in 
the quasi-2D-cells. Perhaps this is the reason why the linear dependence of the growth rate on 
the supersaturation, eq. (4), is able to adequately describe most of the observations. 
 
5. Conclusion and Recommendations 
The present study focuses on insulin because of its medical significance; insulin 
crystals of definite narrow size distribution are highly needed in medicine. However, the 
authors are convinced that the methodology described can be successfully applied to 
crystallization of other proteins as well. Under the innovative method proposed relatively 
short nucleation times at high supersaturations (due to high initial solute concentration) are 
recommended to grow protein crystals of narrower size distribution. Higher supersaturation 
also allows for higher throughput because it accelerates the crystal growth process. However, 
there is an intrinsic upper limit of supersaturation imposed by the need to avoid nutrition 
competition during crystal growth stage. 
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